WAKEFIELD, MA--(Marketwired - May 22, 2014) - TraceLink Inc., the leader in pharmaceutical serialization, track and trace and supply network towers for global Life Sciences, announced today that Brian Daleiden, TraceLink's Vice President of Marketing, will speak on the US Drug Supply Chain Security Act (DSCSA) at the 4th University of Wurzburg Anti-Counterfeit Conference taking place May 26-27, 2014 in Wurzburg, Germany.
During the conference focused on Strategies against Falsified / Counterfeit Medicines, Mr. Daleiden will review the new DSCSA law which phases in starting January 1, 2015 for companies across the pharmaceutical supply chain. DSCSA, Title II of the Drug Quality and Security Act, implements new regulations governing the track and trace of drug products across all changes of ownership from pharmaceutical manufacturer to pharmacy dispenser.
Conference participants will hear Mr. Daleiden provide a detailed overview of:
- The core DSCSA Tracing, Verification and Serialization regulations
- Unique compliance issues facing manufacturers, repackagers, wholesale distributors and pharmacy dispensers
- DSCSA data exchange challenges and industry approaches such as HDMA ASN, GS1 EPCIS and secure web portals
- Business process impacts and operational use case considerations
- FDA and industry stakeholder collaborations to facilitate DSCSA implementation
- A strategy and planning checklist to prepare a DSCSA compliance roadmap for success
TraceLink recently announced its TraceLink Life Sciences Cloud version 5.0 with Product Track, the industry's first Transaction History Management System for end-to-end DSCSA compliance. Product Track delivers an integrated DSCSA Tracing, Verification and Serialization solution for the unique requirements of all companies across the pharmaceutical supply chain, including flexible HDMA ASN, GS1 EPCIS and secure web portal data exchange.
TraceLink's global track and trace applications are trusted by eight of the top 12 pharmaceutical companies, connecting over 47,000 trading partners and endpoints to meet US, China, Brazil and other compliance requirements.
Learn more about TraceLink's pharmaceutical track and trace solutions and supply network tower applications at www.tracelink.com.
TraceLink protects patients, enables health, grows profits and ensures compliance for companies across the global Life Sciences network through the TraceLink Life Sciences Cloud. The TraceLink Life Sciences Cloud is an Amazon AWS Cloud-based application platform which enables complete global connectivity, visibility and traceability of pharmaceuticals from ingredient to patient. A single point and click connection to the Life Sciences Cloud delivers the information, insight and collaboration needed to improve performance and reduce risk across global supply, manufacturing and distribution operations. Winner of numerous industry awards including the Amazon AWS Global Start-Up Challenge Grand Prize and the Edison Award for Innovation in Health Management, TraceLink is trusted by businesses across the globe to meet strategic goals in ensuring global compliance, fighting drug counterfeiting, improving on-time and in-full delivery, protecting product quality and reducing operational cost. Visit www.tracelink.com or follow us on LinkedIn.
TraceLink is funded by FirstMark Capital. FirstMark Capital is an early stage venture capital firm based in New York City. FirstMark's mission is to partner with exceptional entrepreneurs who are changing the world by solving meaningful problems. FirstMark has built a deeply engaged community among the extraordinary teams in the FirstMark network to spread ideas and opportunities. FirstMark is privileged to work alongside the founders of remarkable businesses like Pinterest, Lumosity, Aereo, TapAd, Shopify, Riot Games, and dozens more. Visit FirstMark in New York City or online at firstmarkcap.com and @FirstMarkCap.